33 related articles for article (PubMed ID: 17940564)
1. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
2. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Dimitrov G; Shousha S; Troianova P
Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer.
Yang ZG; Ren LH; Wang F; Wang PL; Wang WY; Lin SY
Curr Med Sci; 2024 Feb; 44(1):156-167. PubMed ID: 38302780
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.
Dou H; Li F; Wang Y; Chen X; Yu P; Jia S; Ba Y; Luo D; Gao T; Li Z; Xiao M
Diagn Pathol; 2024 Jan; 19(1):5. PubMed ID: 38178166
[TBL] [Abstract][Full Text] [Related]
5. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients.
Wu YT; Li X; Lu LJ; Gan L; Dai W; Shi YL; Adhikari VP; Wu KN; Kong LQ
J Biomed Res; 2017 Nov; 32(3):191-7. PubMed ID: 29770779
[TBL] [Abstract][Full Text] [Related]
6. Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.
Abdel-Fatah TMA; Ball GR; Thangavelu PU; Reid LE; McCart Reed AE; Saunus JM; Duijf PHG; Simpson PT; Lakhani SR; Pongor L; Gyorffy B; Moseley PM; Green AR; Pockley AG; Caldas C; Ellis IO; Chan SYT
JAMA Netw Open; 2020 Jul; 3(7):e209486. PubMed ID: 32633764
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.
Posso M; Corominas JM; Serrano L; Román M; Torá-Rocamora I; Domingo L; Romero A; Quintana MJ; Vernet-Tomas M; Baré M; Vidal C; Sánchez M; Saladié F; Natal C; Ferrer J; Servitja S; Sala M; Castells X;
Cancer Med; 2017 Jun; 6(6):1482-1489. PubMed ID: 28470951
[TBL] [Abstract][Full Text] [Related]
8. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
Abubakar M; Chang-Claude J; Ali HR; Chatterjee N; Coulson P; Daley F; Blows F; Benitez J; Milne RL; Brenner H; Stegmaier C; Mannermaa A; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RAEM; Seynaeve C; Figueroa J; Lissowska J; Hewitt S; Hooning MJ; Hollestelle A; Foekens R; Koppert LB; ; Bolla MK; Wang Q; Jones ME; Schoemaker MJ; Keeman R; Easton DF; Swerdlow AJ; Sherman ME; Schmidt MK; Pharoah PD; Garcia-Closas M
Int J Cancer; 2018 Aug; 143(4):746-757. PubMed ID: 29492969
[TBL] [Abstract][Full Text] [Related]
9. The effect of prolonged neoadjuvant endocrine therapy on the efficacy of treatment with breast cancer.
Qin Q; Han X; Li H; Zhou SY; Wang CH; Zhang GL
Technol Health Care; 2023; 31(6):2059-2071. PubMed ID: 37393441
[TBL] [Abstract][Full Text] [Related]
10. Mammographic assessment of breast density as a tool for predicting the response to neoadjuvant therapy in breast cancer patients.
Lisencu LA; Roman A; Paşca A; Irimie A; Lisencu C; Negrutiu M; Fetica B; Cismaru A; Balacescu O; Tudoran O; Lisencu C
Med Pharm Rep; 2024 Jan; 97(1):43-55. PubMed ID: 38344331
[TBL] [Abstract][Full Text] [Related]
11. Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.
Chung SH; Feldman MD; Martinez D; Kim H; Putt ME; Busch DR; Tchou J; Czerniecki BJ; Schnall MD; Rosen MA; DeMichele A; Yodh AG; Choe R
Breast Cancer Res; 2015 May; 17():72. PubMed ID: 26013572
[TBL] [Abstract][Full Text] [Related]
12. The role of preoperative systemic treatment in patients with breast cancer.
Dębska-Szmich S; Krakowska M; Czernek U; Habib-Lisik M; Zięba A; Potemski P
Contemp Oncol (Pozn); 2016; 20(2):93-101. PubMed ID: 27358586
[TBL] [Abstract][Full Text] [Related]
13. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
Hadad SM; Jordan LB; Roy PG; Purdie CA; Iwamoto T; Pusztai L; Moulder-Thompson SL; Thompson AM
BMC Cancer; 2016 Sep; 16(1):745. PubMed ID: 27658825
[TBL] [Abstract][Full Text] [Related]
14. The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy.
Meneveau MO; Crawford MP; Turkheimer LM; Millard TA; Atkins KA; Showalter SL
Ann Surg Oncol; 2023 Oct; 30(10):6034-6040. PubMed ID: 37454014
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.
Tao M; Chen S; Zhang X; Zhou Q
Medicine (Baltimore); 2017 Dec; 96(51):e9384. PubMed ID: 29390540
[TBL] [Abstract][Full Text] [Related]
16. [Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients].
Wei Y; Li JF; Wang TF; Xie YT; Fan ZQ; Fan T; Lu AP; Ouyang T; Lin BY
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Oct; 39(5):481-3. PubMed ID: 17940564
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
